SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt

Bo Feldt-Rasmussen, Rikke Borg, Jan Carstens, Ditte Hansen, Mads Hornum, Morten Lindhardt, Frank Holden Mose, Birgitte Bang Pedersen, Johan Vestergaard Poulsen, Kristine Dyhr Schandorff, Charlotte Strandhave

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Abstract

This review summarises the current knowledge of electroconvulsive therapy (ECT) which is still the most potent and fast-acting antidepressant intervention. The modern procedure is safe when general precautions are taken. Cognitive side effects are transient in most patients, and concerns about side effects should not prevent relevant use. Due to the prognostic benefits of rapid remission, ECT should, in relevant patients, be considered early in the treatment course. Patients should be offered maintenance pharmacotherapy, and, in high-risk cases, tapering of the acute ECT course or maintenance ECT, in order to reduce the risk of relapse.

Bidragets oversatte titelSGLT2 inhibitorsfor treatment of chronic kidney disease without diabetes or heart failure
OriginalsprogDansk
ArtikelnummerV11210887
Antal sider8
TidsskriftUgeskrift for laeger
Vol/bind184
Udgave nummer16
StatusUdgivet - 18 apr. 2022

Emneord

  • Diabetes Mellitus
  • Electroconvulsive Therapy/adverse effects
  • Female
  • Heart Failure/drug therapy
  • Humans
  • Male
  • Renal Insufficiency, Chronic/complications
  • Sodium-Glucose Transporter 2

Fingeraftryk

Udforsk hvilke forskningsemner 'SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt' indeholder.

Citationsformater